SPR Therapeutics LOGO 361 TM.jpg
SPR® Therapeutics Announces $85 Million in Additional Funding to Advance Rapid Commercial Expansion of the SPRINT® PNS System
February 01, 2024 09:00 ET | SPR Therapeutics, Inc.
SPR Therapeutics Announces $85 Million in Additional Funding to Advance Commercial Expansion of SPRINT PNS System.
SPR Therapeutics LOGO 361 TM.jpg
SPR® Therapeutics Announces Extensive Set of Abstracts to be Shared at North American Neuromodulation Society (NANS) Annual Meeting 2024
January 16, 2024 09:00 ET | SPR Therapeutics, Inc.
SPR Therapeutics and the SPRINT PNS System will be featured prominently at the North American Neuromodulation Society Annual Meeting with 11 abstracts.
SPR Therapeutics LOGO 361 TM.jpg
SPR Therapeutics Announces Completion of Enrollment in the RESET Clinical Trial of the SPRINT® PNS System for Low Back Pain
December 12, 2023 11:48 ET | SPR Therapeutics, Inc.
SPR Therapeutics Announces Completion of Enrollment in the RESET Clinical Trial of the SPRINT PNS System for Low Back Pain
SPR Therapeutics LOGO 361 TM.jpg
New SPR Therapeutics Data Presented at ASRA Pain Medicine Meeting 2023
November 13, 2023 09:05 ET | SPR Therapeutics, Inc.
Three SPR Posters Accepted Including a President’s Choice Award for New Data from Randomized Controlled Trial on Total Knee Replacement Postoperative Pain
SPR Therapeutics LOGO 361 TM.jpg
SPR Therapeutics Announces 20,000th Patient Implant of SPRINT® PNS System
August 22, 2023 10:00 ET | SPR Therapeutics, Inc.
CLEVELAND, Aug. 22, 2023 (GLOBE NEWSWIRE) -- SPR® Therapeutics, a private medical device company focused on treating pain and improving the quality of life for patients managing acute or chronic...
SPR Therapeutics LOGO 361 TM.jpg
SPR Therapeutics Named a Top Workplace for Second Consecutive Year
June 25, 2023 08:00 ET | SPR Therapeutics, Inc.
- Company maintains focus on employee engagement and success while experiencing dynamic growth - CLEVELAND, June 25, 2023 (GLOBE NEWSWIRE) -- SPR Therapeutics has been selected as a Top...
SPR Therapeutics LOGO 361 TM.jpg
Real-World Data from Over 6,100 Patients Corroborates Significant Pain Reduction from Prior Prospective Studies for Patients Treated with SPRINT® PNS
May 17, 2023 10:16 ET | SPR Therapeutics, Inc.
CLEVELAND, May 17, 2023 (GLOBE NEWSWIRE) -- SPR® Therapeutics announced the publication of a comprehensive real-world retrospective data analysis of over 6,100 patients demonstrating significant...
SPR Therapeutics LOGO 361 TM.jpg
SelectHealth Initiates Peripheral Nerve Stimulation (PNS) Coverage to Support Patient Need for Effective Non-opioid Pain Treatment
May 04, 2023 11:07 ET | SPR Therapeutics, Inc.
CLEVELAND, May 04, 2023 (GLOBE NEWSWIRE) -- SelectHealth, a non-profit health plan with over one million members, has demonstrated leadership amid the opioid crisis by creating one of the first...
SPR Therapeutics LOGO 361 TM.jpg
New SPRINT extensa XT™ System with Bimodal PNS™ Offers Synergistic Treatment of Pain
April 25, 2023 10:00 ET | SPR Therapeutics, Inc.
CLEVELAND, Ohio, April 25, 2023 (GLOBE NEWSWIRE) -- SPR® Therapeutics, a private medical device company focused on treating pain and improving the quality of life for patients managing acute or...
SPR Therapeutics LOGO 361 TM.jpg
SPR Therapeutics’ 14-Month Data from Multicenter Low Back Pain Trial Demonstrates Significant, Durable Impacts on Pain Intensity, Disability, and Pain Interference
March 16, 2023 08:00 ET | SPR Therapeutics, Inc.
CLEVELAND, March 16, 2023 (GLOBE NEWSWIRE) -- SPR Therapeutics, a private medical device company focused on treating pain and improving the quality of life for patients suffering from acute or...